Natural products and
anti-inflammatory agents including cyclooxygenase-2 (COX-2) inhibitors which is
a type of nonsteroidal anti-inflammatory drugs (NSAIDs) are highly considerable
interest for the prevention of carcinogenesis. The objective of this study is
to evaluate the oxidative status of colitis-associated cancer induced by azoxymethane
(AOM)/dextran sulfate sodium (DSS), and the effects of COX-2 inhibitor in mice.
Totally 40 mice were randomized and divided to four groups. All animals except
control and Cox-2 inhibitor alone group received AOM/DSS to establish
colitis-associated cancer model as reported elsewhere. COX-2 preferential
inhibitor meloxicam was used to minimize side effects such as gastrointestinal
hemorrhage. Meloxicam were used (5mg/kg, intraperitoneal) three times a week
with meloxicam alone and AOM/DSS + meloxicam group. Superoxide dismutase (SOD),
Glutathione peroxidase (GPx), Malondialdehyde (MDA) and Advanced Oxidation
Protein Products (AOPP) which all of them are oxidative stress markers were
measured by spectrophotometrically. The combination treatment of Meloxicam and
AOM/DSS significantly increased (P< 0.05) SOD activities in mice. GPx
activities were found significantly increased (P< 0.05) in Meloxicam and
AOM/DSS combinations or alone. There were no differences between the control
and treatment groups of MDA levels. AOPP levels of Meloxicam and AOM/DSS
combination group were found higher than the other groups. Meloxicam and /or
AOM/DSS treatment not caused lipid peroxidations, but increased the antioxidant
enzymes and Advanced Oxidation Protein Products levels.
Primary Language | English |
---|---|
Subjects | Veterinary Surgery |
Journal Section | Articles |
Authors | |
Publication Date | September 9, 2019 |
Published in Issue | Year 2019 |